Claims
- 1. A compound according to formula I wherein:R1 is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; aryl of 6 to 10 carbon atoms, optionally substituted with one or two groups selected independently from R5; cycloalkyl of 3 to 8 carbon atoms, optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; or heteroaryl-(CH2)0-6-wherein the heteroaryl group is 5 to 6 membered with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R5; A is —S—, —SO— or SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 6 membered heterocyclic ring containing N—R7 optionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; R5 is H, C7-C11 aroyl, C2-C6 alkanoyl, C1 to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, F, Cl, Br, I, CN, CHO, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkoxyaryl, C1-C6 alkoxyheteroaryl, C1-C6 alkylamino-C1-C6 alkoxy, C1-C2 alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyl, S(O)n—C1-C6 alkyl, S(O)n-aryl where n is 0, 1 or 2; OCOO C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COO C1-C6, alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, —NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; or saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, wherein C1-C6 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, C1 to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C1 to C6 perfluoro alkyl, S(O)n—C1-C6 alkyl S(O)n aryl where n is 0, 1 or 2; or COheteroaryl, wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is hydrogen or a pharmaceutically acceptable salt thereof.
- 2. A compound according to claim 1 wherein:R1 is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; aryl of 6 to 10 carbon atoms, optionally substituted with one to two groups selected independently from R5; cycloalkyl of 3 to 8 carbon atoms, optionally substituted with one to two groups selected independently from R5; saturated or unsaturated mono or bicyclic heterocycle of from 5 to 10 members containing one heteroatom selected from O, S or NR7, optionally substituted with one to two groups selected independently from R5; or heteroaryl-(CH2)0-6-wherein the heteroaryl group is 5 to 6 membered with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R5; A is —S—, —SO— or SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 6 membered heterocyclic ring containing N—R7 optionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; R5 is H, F, Cl, Br, I, CN, CHO, C7-C11 aroyl, C2-C6 alkanoyl, C1 to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkoxyaryl, C1-C6 alkoxyheteroaryl, C1-C6-alkylamino-C1-C6 alkoxy, C1-C2-alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyl, S(O)n—C1-C6 alkyl, S(O)n-aryl where n is 0, 1 or 2; OCOO—C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COO—C1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, NR6CONR6R6, NHSO2CF3, O2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; or saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7; wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected independently from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, C1 to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C1 to C6 perfluoro alkyl, S(O)n alkyl or aryl where n is 0, 1, or 2; or COheteroaryl; wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 3. A compound according to claim 2 whereinR1 is phenyl, naphthyl, alkyl of 1-18 carbon atoms or heteroaryl such as pyridyl, thienyl, imidazolyl or furanyl, optionally substituted with C1-C6 alkyl, C1-C6 alkoxy, C6-C10 aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, halogen; or S(O)n—C1-C6alkyl C1-C6 alkoxyaryl or C1-C6 alkoxyheteroaryl; A is —S—, —SO— or —SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 6 membered heterocyclic ring containing N—R7 optionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; R5 is H, C7-C11 aroyl, C2-C6 alkanoyl, C1 to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, F, Cl, Br, I, CN, CHO, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkylamino-C1-C6 alkoxy, C1-C2 alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyl, S(O)n—C1-C6 alkyl, S(O)n-aryl where n is 0, 1 or 2; OCOO C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COOC1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, —NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, wherein C1-C6 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, C1 to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C1 to C6 perfluoro alkyl, S(O)n alkyl or aryl where n is 0, 1 or 2; or COheteroaryl; wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is hydrogen;or a pharmaceutically acceptable salt thereof.
- 4. A method of treating a pathological condition or disorder mediated by matrix metalloproteinases in mammals which comprises administration to a mammal in need thereof a therapeutically effective amount of a matrix metalloproteinase inhibiting compound of the formula wherein:R1 is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; aryl of 6 to 10 carbon atoms, optionally substituted with one or two groups selected independently from R5; cycloalkyl of 3 to 8 carbon atoms, optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; or heteroaryl-(CH2)0-6-wherein the heteroaryl group is 5 to 6 membered with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R5; A is —S—, —SO— or SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 6 membered heterocyclic ring containing N—R7 optionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; R5 is H, C7-C11 aroyl, C2-C6 alkanoyl, C1 to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, F, Cl, Br, I, CN, CHO, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkoxyaryl, C1-C6 alkoxyheteroaryl, C1-C6 alkylamino-C1-C6 alkoxy, C1-C2 alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyl, S(O)n—C1-C6 alkyl, S(O)n-aryl where n is 0, 1 or 2; OCOO C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COO C1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, —NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; or saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, wherein C1-C6 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, C1 to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C1 to C6 perfluoro alkyl, S(O)n—C1-C6 alkyl S(O)n aryl where n is 0, 1 or 2; or COheteroaryl, wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 5. A method according to claim 4 wherein the condition treated is atherosclerosis, atherosclerotic plaque formation, reduction of coronary thrombosis from atherosclerotic plaque rupture, restenosis, MMP-mediated osteopenias, inflammatory diseases of the central nervous system, skin aging, angiogenesis, tumor metastasis, tumor growth, osteoarthritis, rheumatoid arthritis, septic arthritis, corneal ulceration, abnormal wound healing, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, cirrhosis of the liver, glomerular disease of the kidney, premature rupture of fetal membranes, inflammatory bowel disease, or periodontal disease.
- 6. A method according to claim 4 wherein the condition treated is age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization and corneal graft rejection.
- 7. A method of treating a pathological condition or disorder mediated by TNF-α converting enzyme (TACE) in mammals which comprises administration to a mammal in need thereof a therapeutically effective amount of a TACE inhibiting compound of the formula wherein:R1 is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; aryl of 6 to 10 carbon atoms, optionally substituted with one or two groups selected independently from R5; cycloalkyl of 3 to 8 carbon atoms, optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; or heteroaryl-(CH2)0-6-wherein the heteroaryl group is 5 to 6 membered with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R5; A is —S—, —SO— or SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 6 membered heterocyclic ring containing N—R7 optionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; R5 is H, C7-C11 aroyl, C2-C6 alkanoyl, C1 to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, F, Cl, Br, I, CN, CHO, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-6 alkoxyaryl, C1-C6 alkoxyheteroaryl, C1-C6 alkylamino-C1-C6 alkoxy, C1-C2 alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyl, S(O)n—C1-C6 alkyl, S(O)n-aryl where n is 0, 1 or 2; OCOO C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COO C1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, —NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; or saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, wherein C1-C6 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, C1 to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C1 to C6 perfluoro alkyl, S(O)n—C1-C6 alkyl S(O)n aryl where n is 0, 1 or 2, or COheteroaryl, wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is hydrogen; or a pharmaceutically acceptable salt thereof.
- 8. The method according to claim 7 wherein the condition treated is rheumatoid arthritis, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, or HIV infection.
- 9. A pharmaceutical composition comprising a pharmaceutical carrier and a therapeutically effective amount of a matrix metalloproteinase or TACE inhibiting compound according to the formula wherein:R1 is alkyl of 1 to 18 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; aryl of 6 to 10 carbon atoms, optionally substituted with one or two groups selected independently from R5; cycloalkyl of 3 to 8 carbon atoms, optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; or heteroaryl-(CH2)0-6-wherein the heteroaryl group is 5 to 6 membered with one or two heteroatoms selected independently from O, S, and N and may be optionally substituted with one or two groups selected independently from R5; A is —S—, —SO— or SO2—; R2 and R3, taken with the carbon atom to which they are attached, form a 6 membered heterocyclic ring containing N—R7 optionally having one or two double bonds; R4 is hydrogen, alkyl of 1 to 6 carbon atoms, optionally substituted with one or two groups selected independently from R5; alkenyl of 3 to 18 carbon atoms having 1 to 3 double bonds, optionally substituted with one or two groups selected independently from R5; alkynyl of 3 to 18 carbon atoms having 1 to 3 triple bonds, optionally substituted with one or two groups selected independently from R5; phenyl or naphthyl optionally substituted with one or two groups selected independently from R5; C3 to C8 cycloalkyl or bicycloalkyl optionally substituted with one or two groups selected independently from R5; saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, optionally substituted with one or two groups selected independently from R5; R5 is H, C7-C11 aroyl, C2-C6 alkanoyl, C1 to C12 alkyl, C2 to C12 alkenyl, C2-C12 alkynyl, F, Cl, Br, I, CN, CHO, C1-C6 alkoxy, aryloxy, heteroaryloxy, C3-C6 alkenyloxy, C3-C6 alkynyloxy, C1-C6 alkoxyaryl, C1-C6 alkoxyheteroaryl, C1-C6 alkylamino-C1-C6 alkoxy, C1-C2 alkylene dioxy, aryloxy-C1-C6 alkyl amine, C1-C12 perfluoro alkyl, S(O)n—C1-C6 alkyl, S(O)n-aryl where n is 0, 1 or 2; OCOO C1-C6 alkyl, OCOOaryl, OCONR6, COOH, COO C1-C6 alkyl, COOaryl, CONR6R6, CONHOH, NR6R6, SO2NR6R6, NR6SO2aryl, —NR6CONR6R6, NHSO2CF3, SO2NHheteroaryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, SO2NHCOaryl, CONHSO2—C1-C6 alkyl, CONHSO2aryl, NH2, OH, aryl, heteroaryl, C3 to C8 cycloalkyl; or saturated or unsaturated 5 to 10 membered mono or bicyclic heterocycle containing one heteroatom selected from O, S or NR7, wherein C1-C6 alkyl is straight or branched, heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; R6 is H, C1to C18 alkyl optionally substituted with OH; C3 to C6 alkenyl, C3 to C6 alkynyl, C1 to C6 perfluoro alkyl, S(O)n—C1-C6 alkyl S(O)n aryl where n is 0, 1 or 2; or COheteroaryl, wherein heteroaryl is a 5-10 membered mono or bicyclic heteroaryl group having 1 to 3 heteroatoms selected independently from O, S or NR7 and aryl is phenyl or naphthyl, optionally substituted by 1 or 2 groups selected from halogen, cyano, amino, nitro, C1-C6 alkyl, C1-C6 alkoxy, or hydroxy; and R7 is hydrogen; or a pharmaceutically acceptable salt thereof.
Parent Case Info
This application is a divisional application of U.S. Ser. No. 09/140,504, filed Aug. 26, 1998, now U.S. Pat. No. 6,197,791 which is a CIP of U.S. Ser. No. 09/026,372, filed Feb. 19, 1998 now abandoned, which claims the benefit of prior U.S. Provisional Application No. 60/038,899 filed Feb. 27, 1997.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4933367 |
Wolff et al. |
Jun 1990 |
|
5455258 |
MacPherson et al. |
Oct 1995 |
|
5672615 |
MacPherson et al. |
Sep 1997 |
|
Foreign Referenced Citations (5)
Number |
Date |
Country |
0606046 |
Jul 1994 |
EP |
WO9005719 |
May 1990 |
WO |
WO9519961 |
Jul 1995 |
WO |
WO9535275 |
Dec 1995 |
WO |
WO9600214 |
Jan 1996 |
WO |
Non-Patent Literature Citations (6)
Entry |
R.P. Becker et al., Research Focus, vol. 1, 16-26 (1996). |
Nigel Beeley et al., Curr. Opin. Ther. Patents 4(1), 7-16 (1994). |
J.R. Morphy et al., Curr. Medicinal Chem. 2:743-762 (1995). |
Steven K. Davidson et al., Exp. Opin. Ther. Patents 5(2) 1087-1110 (1995). |
John R. Porter et al., Exp. Opin. Ther. Patents 5(12), 1287-1296 (1995). |
Salah Zayed et al., Liebigs Ann. Chem. 195-200 (1973). |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/038899 |
Feb 1997 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09/026372 |
Feb 1998 |
US |
Child |
09/140504 |
|
US |